Gout is a systemic disease, which results from the deposition of monosodium urate crystals (MSU) in tissues.
Acute gout Flare market report provides current treatment practices, emerging drugs, Acute gout Flare market share of the individual therapies, current and forecasted Acute gout Flare market Size from 2017 to 2030 segmented by seven major markets.
Acute gout flares are characterized by distinct inflammatory symptoms (e.g., pain, erythema, swelling), and may cause physical disability, as well as decreased quality of life. Therefore, rapid reduction of auto-inflammation to achieve prompt symptom control is the main goal in managing acute gout. Colchicine, NSAIDs, and glucocorticosteroids are recommended first-line treatment agents for acute gouty flares. The 2016 updated EULAR guidelines recommend considering treatment with an IL-1 inhibitor in patients having frequent flares and in those who are difficult to treat using conventional therapies. Canakinumab is currently the only IL-1 inhibitor that has been registered in Europe for the treatment of gout.
Current guidelines from the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) advise that long-term urate-lowering therapy (ULT), with the aim of maintaining serum urate levels (generally below 6 mg/dL), is key to effective control of gout and should be initiated in the presence of certain clinical features: for example, tophi, frequent gouty attacks (flares; two or more per year), and urate arthropathy.
Effective options for the treatment of the acute attack include non-steroidal anti-inflammatory drugs (NSAIDs), intra-articular corticosteroids and systemic corticosteroid therapy. With respect to efficacy (although not toxicity) the rapidity with which therapy is commenced appears to be more important than which medication is used. The best choice is often determined by whether or not there are contraindications to NSAID use, such as renal or cardiac insufficiency or a history of peptic ulceration.
Provided synovial fluid has been sent for analysis, including culture, it is reasonable to administer intra-articular corticosteroid immediately following joint aspiration (without removing the needle from the joint) when gout appears likely, even though sepsis has not yet been excluded. Systemic corticosteroid therapy can be provided as oral prednisone 20–40 mg daily in divided doses reducing to zero in 10–14 days or intramuscular depot tetracosactrin 1 mg, a synthetic analog of ACTH.
Colchicine used as the primary treatment of the acute attack is associated with a very high rate of gastrointestinal toxicity.
Scope of the Report
• The report covers the descriptive overview of Acute gout Flare , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Acute gout Flare epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Acute gout Flare are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Acute gout Flare market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Acute gout Flare market
Request for sample pages
Table of contents
1. Key Insights
2. Executive Summary of Acute gout Flare
3. Competitive Intelligence Analysis for Acute gout Flare
4. Acute gout Flare : Market Overview at a Glance
4.1. Acute gout Flare Total Market Share (%) Distribution in 2017
4.2. Acute gout Flare Total Market Share (%) Distribution in 2030
5. Acute gout Flare : Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Acute gout Flare Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Acute gout Flare Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Acute gout Flare Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Acute gout Flare Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Acute gout Flare Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Acute gout Flare Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Acute gout Flare Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Acute gout Flare Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Acute gout Flare Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Acute gout Flare Treatment and Management
8.2. Acute gout Flare Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Acute gout Flare Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Acute gout Flare : Seven Major Market Analysis
13.1. Key Findings
13.2. Acute gout Flare Market Size in 7MM
13.3. Acute gout Flare Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Acute gout Flare Total Market Size in the United States
15.1.2. Acute gout Flare Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Acute gout Flare Total Market Size in Germany
15.3.2. Acute gout Flare Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Acute gout Flare Total Market Size in France
15.4.2. Acute gout Flare Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Acute gout Flare Total Market Size in Italy
15.5.2. Acute gout Flare Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Acute gout Flare Total Market Size in Spain
15.6.2. Acute gout Flare Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Acute gout Flare Total Market Size in the United Kingdom
15.7.2. Acute gout Flare Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Acute gout Flare Total Market Size in Japan
15.8.3. Acute gout Flare Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Acute gout Flare
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
*The table of contents is not exhaustive; the final content may vary.
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/